Rhabdomyolysis in a patient taking nebivolol.
β Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial β2 adrenoceptor agonistic effect. Nebivolol has the highest β1 receptor affinity among β blockers, and it has never been reported to induce rhabdomyolysis until now. We report a patient who developed rhabdomyolysis after changing medication to nebivolol. A 75-year-old woman was admitted to our hospital because of generalized weakness originating 2 weeks before visiting. Approximately 1 month before her admission, her medication was changed from carvedilol 12.5 mg to nebivolol 5 mg. Over this time span, she had no other lifestyle changes causing rhabdomyolysis. Her blood chemistry and whole body bone scan indicated rhabdomyolysis. We considered newly prescribed nebivolol as a causal agent. She was prescribed carvedilol 12.5 mg, which she was previously taking, instead of nebivolol. She was treated by hydration and urine alkalization. She had fully recovered and was discharged.
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Ye Jin
YJ
Kim
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Hae Ri
HR
Kim
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Hong Jae
HJ
Jeon
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Hyun Jun
HJ
Ju
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Sarah
S
Chung
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Dae Eun
DE
Choi
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Kang Wook
KW
Lee
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Ki Ryang
KR
Na
Myopathies; Nebivolol; Rhabdomyolysis; β-adrenergic blockers
Ann Pharmacother. 2001 Sep;35(9):1096-107
11573861
Am J Med. 2006 May;119(5):400-9
16651050
Br Med J. 1978 Sep 16;2(6140):833
698761
Am J Cardiovasc Drugs. 2010;10(3):175-86
20524719
J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9
19815121
JAMA. 2004 Sep 15;292(11):1307-16
15337732
Am Heart J. 2001 Jun;141(6):899-907
11376302
Cardiovasc Ther. 2008 Fall;26(3):189-202
18786089
J Card Fail. 2011 Sep;17(9):703-9
21872138
Br J Pharmacol. 2004 Jun;142(4):667-70
15159279
Physiol Rev. 2008 Apr;88(2):729-67
18391178
Nucl Med Rev Cent East Eur. 2005;8(2):153-4
16437405
N Engl J Med. 2009 Jul 2;361(1):62-72
19571284
Am J Cardiol. 2013 Mar 1;111(5):765-9
23290925
Circulation. 2000 Jan 18;101(2):207-13
10637210
Am J Physiol Cell Physiol. 2006 Dec;291(6):C1208-12
16885396
Rinsho Shinkeigaku. 1990 Jan;30(1):103-6
2331815
Pediatr Neurol. 1990 Jul-Aug;6(4):275-6
2206162
Nat Biotechnol. 2008 Mar;26(3):343-51
18297058
Eur Heart J. 2012 Jul;33(13):1635-701
22555213
Am Heart J. 2010 Mar;159(3):428-33
20211305
Radiographics. 1993 Jul;13(4):715-34
8356264
Drug Saf. 2000 Jun;22(6):441-57
10877038
J Am Coll Cardiol. 2007 Jul 31;50(5):409-18
17662392
Cardiovasc Drugs Ther. 1998 Sep;12(4):339-44
9825177
Br J Clin Pharmacol. 1990 Nov;30(5):665-72
1980200
BMC Res Notes. 2013 Feb 06;6:52
23388500
Crit Care Med. 2005 Jun;33(6):1311-6
15942349
J Clin Pharmacol. 1996 Aug;36(8):760-3
8877682
J Nucl Med Technol. 2003 Sep;31(3):149-53; quiz 154-6
12968045
J Am Soc Nephrol. 2000 Aug;11(8):1553-61
10906171
Am J Cardiol. 2005 Feb 15;95(4):462-8
15695129
Am J Cardiovasc Drugs. 2008;8(1):35-44
18303936
J Pediatr Gastroenterol Nutr. 1990 May;10(4):544-7
1972743
Hum Toxicol. 1985 Jan;4(1):57-60
3988305
Clin Infect Dis. 1996 Apr;22(4):642-9
8729203
Clin Exp Rheumatol. 1994 May-Jun;12 (3):309-11
8070166
J Cardiovasc Pharmacol. 1988 May;11(5):552-63
2455841